Comparative Pharmacology
Head-to-head clinical analysis: RESPORAL versus VANTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RESPORAL versus VANTIN.
RESPORAL vs VANTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
Cefpodoxime proxetil is a semisynthetic third-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
2 mg orally twice daily
100-200 mg orally twice daily for 10-14 days for community-acquired pneumonia; 100 mg orally twice daily for 5-7 days for acute exacerbations of chronic bronchitis; 100 mg orally twice daily for 10 days for uncomplicated skin and skin structure infections; 100 mg orally twice daily for 3-7 days for uncomplicated urinary tract infections; 200 mg orally twice daily for 10 days for complicated urinary tract infections.
None Documented
None Documented
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
The terminal elimination half-life in adults with normal renal function is about 2.2-2.8 hours. In children, it is approximately 1.5-2 hours. Prolonged half-life in renal impairment (up to 9-10 hours in severe impairment) requires dose adjustment.
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Approximately 80-90% of cefpodoxime is excreted unchanged in the urine within 24 hours, mainly by glomerular filtration and tubular secretion. A small fraction is eliminated via bile and feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic